The Value Of Serum TSP-1 In The Prognosis Diagonsis Of In Non-small Cell Lung Cancer

Objective:Most lung cancer is non-samll cell lung cancer(NSCLC),the incidence rate is high,lung cancer has been diagnosed with advanced lung cancer.Studies have shown that platelet reactive TSP-1with different degrees of expression in lung cancer progression,specifically in the inhibition of cell adhesion,inhibit angiogenesis and inhibit tumor growth.This study through the detection of serum TSP-1 concenration in patients with NSCLC the degree of differential expression before and after chemotherapy,to explore whether it can provide the clinical progonsis the value of NSCLC.Methods:The experimental group from October 1,2015 to Ottober 31,2016 in the deparetment of internal medicine Yijishan hospital,Wannan Medical College in two Pathologically diagnosed with Non-small cell lung cancer patients undergoing chemotherapy.48 cases of concurrent chemotherapy selection is based on individualized treatment and comprehensive NCCN guidelines recommend the patient’s own situation.The healthy control group from the same physical examination center of the First Affiliated Hospital Health Examination who(ethical committee approval)in 20 cases.Through the detection of patients with lung cancer group and the experimental group before the first chemotherapy,third time before chemotherapy,the serum TSP-1concentration of fifth times before chemotherapy(the value of the specific operation is to extract the patient admitted to hospital second days fasting venous blood)),in the end after 4 cycle of chemotherapy to evaluate the efficacy of chemotherapy.To observe whether there is a correlation between the efficacy of chemotherapy and the concentration of TSP-1.Data were collected including age,gender,smoking history,blood routine,tumor markers,pathological type,physical status score,severity evaluation,chemotherapy and so on.Results:One,the experimental group and control group,the platelet count between groups found that P value is greater than 0.05,with the concentration of TSP-1 in experimental group hemagglutinationconventional completely normal and incomplete normal values were not significant.Two,The concentration of TSP-1,NSCLC patients before chemotherapy for the first time,the third time before chemotherapy,fifth time before chemotherapy serum TSP-1 concentration was significantly lower than taht of control group(P<0.01).Three,according to the patient assessment data of the experimental group were divided into specific CR(complete remission,0cases),PR(partial remission,20 cases),SD(stable disease,18 cases),PD(progression disease,10 cases).The three groups were compared th eserum TSP-1 concentration with before the first chemotherapy,third times before chemotherapy,fifth times before chemotherapy,TSP-1 concentration was found in PR group increased(P<0.01),SD group before and after chemotherapy the concentration changes of TSP-1 were not significantly different(P>0.05),PD group TSP-1 concentration decreased(P<0.01);comparision before the first chemotherapy,third time before chemotherapy,fifth after chemotherapy,PR group,SD group,PD group,found that before the first chemotherapy,before the third chemotherapy difference of TSP-1 serum concentration of P is greater tahn 0.05,the fifth time before chemotherapy TSP-1concentration difference between the three groups P value is less than 0.01.Conclusion:The concentration of TSP-1 in serum of NSCLC was sifnificantly lower than that of the normanl population,and the increase and decrease of the concentration of NSCLC in serum were consistent with the evaluation of the curative effect of chemotherapy.The concentration of serum TSP-1 can provide the clinical value for the prognosis of patients.